Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synosia SYN115 Study Shows Positive Results
The phase IIa trial was a randomised, double-blind, placebo-controlled, cross-over study in 24 parkinson’s patients using doses up to 120mg/day for one week. The effects of SYN-115 as
The phase IIa trial was a randomised, double-blind, placebo-controlled, cross-over study in 24 parkinson’s patients using doses up to 120mg/day for one week. The effects of SYN-115 as
CS-8958 is a laninamivir prodrug that is a Long-Acting Neuraminidase Inhibitor. The drug, developed entirely for the Japanese market by Daiichi Sankyo, will be in the form of
Under the terms of the agreement, Lilly will fund a collaborative research and development program with the aim of creating improved drugs incorporating SPL’s proprietary delivery technology, and
The open label, single centre pharmacokinetic study in 20 healthy volunteers was conducted at the Royal Adelaide Hospital. The primary objective of the study was to compare the
Bioflor (Saccharomyces boulardii) is a probiotic antidiarrheal product mainly used in the prevention and treatment of diarrhea, a common gastroentrologic disorder found in adults and children. Under the
Lehigh Press manufactures labels, inserts and outserts and other packaging components, mainly for the pharmaceutical and healthcare markets. Bill Mitchell, CEO of Keller Crescent, said: “This is a
The collaborative sites are expected to provide clinical expertise and samples to evaluate the clinical utility of a microRNA (miRNA) test, based on FNA biopsies, to distinguish pancreatic
Infosys said that Elan and its research partners could realize gains in research productivity by focused and efficient selection of candidate drugs or biologics with the new RISe.
In accordance with the Scheme, all Scheme shares have been transferred to YM and Cytopia is now a wholly-owned subsidiary of YM. The Scheme Consideration, as well as
This facility is likely to provide on-site chemistry resources for Pfizer along with a resource for other developing companies in the vicinity. Tony Wood, vice president of world-wide